Found: 7
Select item for more details and to access through your institution.
Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102.
- Published in:
- Movement Disorders Clinical Practice, 2018, v. 5, n. 2, p. 183, doi. 10.1002/mdc3.12595
- By:
- Publication type:
- Article
A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 5, p. 817, doi. 10.1177/13524585211035333
- By:
- Publication type:
- Article
Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
- Published in:
- Multiple Sclerosis Journal, 2019, v. 25, n. 4, p. 601, doi. 10.1177/1352458518754716
- By:
- Publication type:
- Article
Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Amlodipine Added to Quinapril vs Quinapril Alone for the Treatment of Hypertension in Diabetes: The Amlodipine in Diabetes (ANDI) Trial.
- Published in:
- Journal of Clinical Hypertension, 2007, v. 9, n. 2, p. 120, doi. 10.1111/j.1524-6175.2007.06949.x
- By:
- Publication type:
- Article
Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia.
- Published in:
- 2019
- By:
- Publication type:
- journal article